Oramed Pharmaceuticals (ORMP) Cash & Equivalents (2010 - 2026)

Oramed Pharmaceuticals (ORMP) has 17 years of Cash & Equivalents data on file, last reported at $13.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 82.28% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (down 82.28% YoY) and the FY2025 annual result came in at $45.9 million, down 15.57% from the prior year.
• Cash & Equivalents retreated to $13.2 million in Q1 2026, from $45.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $84.8 million in Q2 2024 to a low of $435000.0 in Q2 2025.
• A 5-year average of $30.1 million and a median of $28.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 1152.45% — and 2025, when it sank 99.49%.
• Tracing ORMP's Cash & Equivalents over 5 years: stood at $40.5 million in 2022, then tumbled by 77.62% to $9.1 million in 2023, then jumped by 500.99% to $54.4 million in 2024, then retreated by 15.57% to $45.9 million in 2025, then slumped by 71.27% to $13.2 million in 2026.
• The last three Cash & Equivalents figures came in at $13.2 million (Q1 2026), $45.9 million (Q4 2025), and $868000.0 (Q3 2025), per Business Quant data.